Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/12/2003WO2003047500A2 Vaccine and method for treatment of motor neurone diseases
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2003047421A2 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003WO2003047363A1 Methods and compositions for use in pet breeding
06/12/2003WO2003026641A3 Modulation of stat activity
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2003008625A3 Structural and cytoskeleton-associated proteins
06/12/2003WO2002018544A3 Method and reagents for treatment of skin disorders by modulating the notch pathway
06/12/2003WO2002016623A8 Bacterial strains, genes and enzymes for control of bacterial diseases by quenching quorum-sensing signals
06/12/2003WO2002012345A3 Soluble zcytor 11 cytokine receptors
06/12/2003WO2002008389A9 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
06/12/2003WO2001085096A9 Mast cell regulation
06/12/2003WO2001073133A9 Compositions and methods for identifying and targeting cancer cells
06/12/2003WO2000040737A9 High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
06/12/2003US20030110519 Cognition activators, sleep disorders, eating disorders, psychological disorders
06/12/2003US20030110169 System and method for providing manageability to security information for secured items
06/12/2003US20030109743 Cardiovascular disorders
06/12/2003US20030109699 Biopolymers; gene therapy, medical diagnosis
06/12/2003US20030109692 Protein G receptors; autoimmune disease, antidiabetic agents, anticancer agents
06/12/2003US20030109691 Variant integrin polypeptides and uses thereof
06/12/2003US20030109689 Using polypeptides; induction immunology response
06/12/2003US20030109686 Methods for evaluating tissue morphogenesis and activity
06/12/2003US20030109685 Schizophrenic, psychological disorders, Parkinson's disease; genetic engineered polypeptide
06/12/2003US20030109684 Antitumor agents; transforming growth factor
06/12/2003US20030109683 Hybrid proteins; controlling gene expression in gene therapy; Parkinson's disease
06/12/2003US20030109678 Methods and means for regulation of gene expression
06/12/2003US20030109677 TIE-2 ligands, methods of making and uses thereof
06/12/2003US20030109676 Human endothelin-bombesin receptor
06/12/2003US20030109675 Therapy for infections; enzyme inhibitors
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109672 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109670 Conotoxins; sodium channel moderators, calcium channel blockers, analgesics
06/12/2003US20030109557 Calcium channel blockers such as amlodipine in the treatment of renal disease in normotensive animals. Also described are new unit doses of amlodipine suitable for the treatment of renal disease in normotensive cats.
06/12/2003US20030109531 Therapeutic agent composition and method of use
06/12/2003US20030109526 Azo amino acids derivatives
06/12/2003US20030109520 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
06/12/2003US20030109517 Azacycloalkanone serine protease inhibitors
06/12/2003US20030109506 Treating vitamin D responsive diseases
06/12/2003US20030109481 Tumour-cell specific gene expression and its use in cancer therapy
06/12/2003US20030109480 Inhibitors of endothelin-1 synthesis
06/12/2003US20030109478 Nucleic acid formulations for gene delivery and methods of use
06/12/2003US20030109477 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
06/12/2003US20030109475 Introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or
06/12/2003US20030109469 Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
06/12/2003US20030109467 Antisense modulation of human FXR expression
06/12/2003US20030109466 Antisense modulation of KSR expression
06/12/2003US20030109465 TGF- beta blocking agent-treated HSC compositions and methods comprising the same. The TGF- beta blocking agent-treated stem cells are viable for an extended time in culture without replication or differentiation and upon transfer to conditions
06/12/2003US20030109464 Galectins -1 and -4 in tumor development
06/12/2003US20030109458 Oligopeptides which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using compounds for
06/12/2003US20030109457 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
06/12/2003US20030109456 TRI-, TETRA-, and penta-peptides having antiangiogenic activity
06/12/2003US20030109455 HEPTA-, OCTA-and nonapeptides having antiangiogenic activity
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109453 Treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine.
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109448 Enhancing cellular uptake and redistributing gene regulating polyamides from the extranuclear areas in eukaryotic cells to the nucleus thereof. The method consists of administering to the eukaryotic cells a molecular trafficking compound
06/12/2003US20030109447 Methods of use of recombinant vasoactive protein from salivary gland of the black fly
06/12/2003US20030109446 Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
06/12/2003US20030109445 Methods and compositions for the treatment and prevention of parkinson's disease
06/12/2003US20030109444 Bone anti-resorptive compounds
06/12/2003US20030109443 Determining the prognosis for treatment of, and methods for identifying candidate compounds for treating, stabilizing, or preventing cancer, for example, endometrial cancer. These methods utilize the novel tumor suppressor protein, Cables.
06/12/2003US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally
06/12/2003US20030109441 Use of lactogenic and somatogenic hormones to enhance reproductive efficiency in mammals
06/12/2003US20030109439 Keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163 in lower concentrations
06/12/2003US20030109438 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109433 Protection against ischemia and reperfusion injury
06/12/2003US20030109432 Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
06/12/2003US20030109431 Synthetic tetrapeptide having an amino acide sequence, Glycine- Proline-Arginine-Proline (GPRP) has pro-inflammatory effects on human fibroblastic cells, including synovial cells. An amide analog of GPRP is ineffective in inducing, or
06/12/2003US20030109430 Immunoassays for human and canine brain natriuretic peptide
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109428 Novel molecules of the card-related protein family and uses thereof
06/12/2003US20030109427 Highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density
06/12/2003US20030109426 Cyclosporins for the treatment of respiratory diseases
06/12/2003US20030109425 Cyclosporin analogs of the present invention or a pro-drug or pharmaceutically acceptable salt thereof in pharmaceutical compositions for the treatment of asthma and other diseases characterized by airflow obstruction in a subject
06/12/2003US20030109424 Solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles.
06/12/2003US20030109423 Cyclin- dependent kinases (Cdks) are important for driving cells through different phases of the cell cycle and their sequential activation and deactivation are tightly regulated activation of the mitotic Cdk, Cdc2, requires multiple events;
06/12/2003US20030109422 Process for the preparation of pharmaceutical formulations containing lactoferrin
06/12/2003US20030109418 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030109044 Methods of using 279, a human G protein-coupled protein receptor
06/12/2003US20030109026 Genetically modified tumor-targeted bacteria with reduced virulence
06/12/2003US20030109022 Asp2
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030109008 Cell proliferation, cell differentiation; stem cells
06/12/2003US20030109004 Culture product; cell transformation; genetic engineering using promoter
06/12/2003US20030109002 SIRP proteins and uses thereof
06/12/2003US20030109000 Culture product; binding polypeptides containing activated end groups
06/12/2003US20030108998 Aggrecan degrading metallo proteases
06/12/2003US20030108994 Antibodies that bind human Zven1
06/12/2003US20030108993 Human mitochondrial chaperone protein
06/12/2003US20030108989 Mixture of genetic engineered protein and carrier; trauma therapy for humans, animals
06/12/2003US20030108984 CD44 splice variant associated with rheumatoid arthritis
06/12/2003US20030108983 Secreted and transmembrane polypeptides and nucleic acids encoding the same
1 ... 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 ... 3163